Payment overview · 2025
General Payments
$2,752.77
70 reported records · 23 companies
Healthcare provider profile · identity verified
Daniel Jay Glatt, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BURLINGAME, CA · NPI 1649228917
Verified facts
What the public records show
CMS Open Payments records show Daniel Jay Glatt, MD received $2,752.77 in general payments during 2025 across 70 reported records.
Indivior Inc. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Creon, Eliquis, Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Belbuca by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Nucynta by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $1,155.59 | 42.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.56 | 5.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $154.12 | 5.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $151.69 | 5.5% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $107.51 | 3.9% | 5 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $103.61 | 3.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.43 | 3.5% | 4 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $95.14 | 3.5% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $84.05 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.07 | 3.0% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $79.53 | 2.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $78.07 | 2.8% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $74.15 | 2.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.90 | 1.9% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $51.36 | 1.9% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.06 | 1.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.41 | 1.6% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $30.04 | 1.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.78 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.06 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.73 | 0.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.66 | 0.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.25 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,880.82 | 67 |
| Travel and Lodging | $871.95 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $1,155.59 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $193.45 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $151.69 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $122.71 | 5 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $103.61 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $95.14 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $87.02 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $79.53 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $74.15 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.18 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.18 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $51.76 | 3 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $51.36 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $51.13 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $50.91 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.07 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.41 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $41.52 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.32 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.64 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 58 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 419 | 148 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 47 |
| Oxycodone Hcl | Oxycodone Hcl | 362 | 43 |
| Gabapentin | Gabapentin | 285 | 84 |
| Morphine Sulfate Er | Morphine Sulfate | 229 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 69 |
| Fentanyl | Fentanyl | 182 | 21 |
| Famotidine | Famotidine | 176 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 162 | 26 |
| Oxycontin | Oxycodone Hcl | 156 | 16 |
| Trazodone Hcl | Trazodone Hcl | 156 | 50 |
| Lisinopril | Lisinopril | 149 | 58 |
| Methadone Hcl | Methadone Hcl | 128 | 17 |
| Pregabalin | Pregabalin | 125 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 41 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 111 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 40 |
| Buspirone Hcl | Buspirone Hcl | 106 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 32 |
| Metformin Hcl Er | Metformin Hcl | 103 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 44 |
| Omeprazole | Omeprazole | 94 | 34 |
| Hydromorphone Hcl | Hydromorphone Hcl | 93 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 30 |
| Celecoxib | Celecoxib | 91 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 35 |
| Alprazolam | Alprazolam | 82 | suppressed |
| Jardiance | Empagliflozin | 77 | 22 |
| Rybelsus | Semaglutide | 73 | 18 |
| Meloxicam | Meloxicam | 72 | 25 |
| Nucynta | Tapentadol Hcl | 70 | 12 |
| Buprenorphine | Buprenorphine | 69 | 15 |
| Metformin Hcl | Metformin Hcl | 68 | 23 |
| Losartan Potassium | Losartan Potassium | 67 | 27 |
| Allopurinol | Allopurinol | 65 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 11 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 59 | 13 |
| Hydromorphone Er | Hydromorphone Hcl | 59 | suppressed |
| Eliquis | Apixaban | 58 | 15 |
| Topiramate | Topiramate | 56 | 15 |
| Xtampza Er | Oxycodone Myristate | 54 | suppressed |
| Lorazepam | Lorazepam | 50 | 17 |
| Testosterone | Testosterone | 46 | suppressed |
| Fluconazole | Fluconazole | 45 | 24 |
| Mirtazapine | Mirtazapine | 45 | 14 |
| Nucynta Er | Tapentadol Hcl | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 16 |
| Furosemide | Furosemide | 41 | 18 |
| Belbuca | Buprenorphine Hcl | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 16 |
| Nabumetone | Nabumetone | 36 | suppressed |
| Finasteride | Finasteride | 35 | 16 |
| Irbesartan | Irbesartan | 34 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 17 |
| Baclofen | Baclofen | 32 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 13 |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | 11 |
| Simvastatin | Simvastatin | 28 | 12 |
| Valsartan | Valsartan | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | 11 |
| Atenolol | Atenolol | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 11 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Savella | Milnacipran Hcl | 22 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Oxymorphone Hcl | Oxymorphone Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Symproic | Naldemedine Tosylate | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,752.77 · 70 records | Indivior Inc. | AIRSUPRA, Belbuca, CAPLYTA, CREON, Cologuard Collection Kit, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, Fluad, Flucelvax, INGREZZA, JARDIANCE, JOURNAVX, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, RELISTOR, REXULTI, SUBLOCADE, TRINTELLIX, The Cologuard Plus Collection Kit, Tlando, VIVITROL, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error